ALS drug will be pulled from Canada, U.S. markets after failed trial – GLOBAL
April 4, 2024
Amylyx Pharmaceuticals will withdraw its amyotrophic lateral sclerosis (ALS) drug – its only product in the market – from the U.S. and Canada after the treatment failed in a key late-stage trial.
The drugmaker on Thursday also announced a 70 per cent reduction in its workforce. It had 384 full-time employees at the end of 2023.
Why it’s important
The ALS drug, branded Relyvrio, was approved in 2022 after lobbying by patient groups who pointed to limited options to treat the potentially fatal disease.
ALS causes progressive paralysis and death, and affects roughly 60,000 people in the U.S. and Europe.
Read more: https://globalnews.ca/news/10402025/als-drug-relyvrio-canada-market/
